Sign inCreate account

Report workspace tools

NCT02327546COMPLETEDanonymous

An Open-Label, Randomized, Single-Dose Study to Evaluate the Effects of 325 mg Ferrous Sulfate Tablet (65 mg Iron) on the Pharmacokinetics of 450 mg Dose of AKB-6548 in Healthy Male Volunteers.

Sponsor

Source record

Akebia Therapeutics

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

AKB-6548

Indication / condition

AI-normalized

Healthy Volunteers

Intervention

Source record

AKB-6548, Ferrous Sulfate

Source & freshness

Source record

NCT ID

NCT02327546

Original source

ClinicalTrials.gov

Source last updated

Nov 14, 2018

Ingested at

Jun 03, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02327546

Title

An Open-Label, Randomized, Single-Dose Study to Evaluate the Effects of 325 mg Ferrous Sulfate Tablet (65 mg Iron) on the Pharmacokinetics of 450 mg Dose of AKB-6548 in Healthy Male Volunteers.

Sponsor

Akebia Therapeutics

Status

COMPLETED

Phase

PHASE1

Condition raw

Healthy Volunteers

Condition normalized

Healthy Volunteers

Modality raw

Healthy Volunteers

Modality normalized

small molecule

Target raw

AKB-6548

Target normalized

AKB-6548

Interventions

AKB-6548, Ferrous Sulfate

Public preview

Source record

This clinical trial, sponsored by Akebia Therapeutics, evaluated the pharmacokinetics of AKB-6548 in healthy male volunteers, specifically assessing the impact of ferrous sulfate on its bioavailability. The study involved a randomized, crossover design with 10 participants.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-Label, Randomized, Single-Dose Study to Evaluate the Effects of 325 mg Ferrous Sulfate Tablet (65 mg Iron) on the Pharmacokinetics of 450 mg Dose of AKB-6548 in Healthy Male Volunteers.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02327546

Status

COMPLETED

Phase

PHASE1

Sponsor

Akebia Therapeutics

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by Akebia Therapeutics, evaluated the pharmacokinetics of AKB-6548 in healthy male volunteers, specifically assessing the impact of ferrous sulfate on its bioavailability. The study involved a randomized, crossover design with 10 participants.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 14, 2018
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02327546

Indication

Healthy Volunteers

Modality

small molecule

Target

AKB-6548

Intervention

AKB-6548, Ferrous Sulfate

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.